Incipient intraductal papillary mucinous neoplasms (IPMNs) are poorly described subcentimeter pancreatic cysts with papillae and mucin similar to IPMNs. They are larger than pancreatic intraepithelial neoplasia but do not meet the cutoff size for IPMNs (Z1 cm). GNAS codon 201 mutations are hallmark genetic alterations of IPMNs. Hence, we sought to determine the GNAS status of incipient IPMNs to better classify these lesions. Incipient IPMNs from 3 institutions were histologically reassessed, manually microdissected, and the genomic DNA was extracted. Using a sensitive digital ligation technique, the mutational status of KRAS at codon 12 and GNAS at codon 201 was determined. We included 21 incipient IPMNs from 7 male and 12 female patients with a median age of 63 years (range, 40 to 76 y). Most patients underwent surgery for pancreatic ductal adenocarcinoma (N = 8) or ampullary adenocarcinoma (N = 3). The median incipient IPMN size was 4 mm (range, 2 to 7 mm), and a majority had gastric-foveolar (N = 11) or intestinal (N = 5) differentiation. The maximum dysplasia observed was intermediate, and most of the lesions had intermediate-grade dysplasia. Mutational analysis revealed KRAS codon 12 mutations in all 21 incipient IPMNs, whereas 7 lesions (33%) in 7 individual patients harbored GNAS codon 201 mutations. The presence of GNAS 201 mutations in incipient IPMNs suggests that a fraction of these cysts are in fact small IPMNs. Morphologically, incipient IPMNs do not appear to be high-risk lesions. Additional studies in a larger cohort are needed to define the relationship of incipient IPMNs to larger IPMNs and, more importantly, to determine their clinical significance.
T hrough steady improvement, widespread availability and decreasing cost of modern imaging, asymptomatic pancreatic cysts are increasingly being detected, and these cysts pose a growing clinical management problem. 1 Studies of autopsy material suggest that pancreatic cysts are present in as many as one fourth of individuals, 2 of which a majority can now be detected on high-resolution cross-sectional imaging. 3 Fortunately, a majority of such cysts are entirely benign, and they do not have to be treated unless they become symptomatic or develop worrisome features on imaging. Numerous comprehensive investigations have been performed to characterize and classify these larger pancreatic cysts on a clinicopathologic and molecular basis with a possible important translational impact on patient treatment. [4] [5] [6] [7] [8] [9] The purpose of the present study is to examine the gray zone occupied by "incipient intraductal papillary mucinous neoplasms (IPMNs)." 10 IPMNs are by definition >1 cm in maximum diameter, whereas pancreatic intraepithelial neoplasias (PanINs) are microscopic. The term "incipient IPMNs" has been used for cystic lesions that fall in between these 2 lesions. Incipient IPMNs are <1 cm in maximum diameter but, in contrast to PanINs, have a number of epithelial features similar to IPMNs, including characteristic long finger-like papillae and prominent mucin production. These lesions are poorly characterized with respect to clinical relevance, pathology, and molecular alterations. Incipient IPMNs are occasionally found in association with familial pancreatic cancer syndromes 10 or in the context of multifocal IPMNs. 11 But they can also be observed in pancreata resected for other indications such as chronic pancreatitis or nonepithelial neoplasms. On the basis of the histologic appearance of the papillae and the epithelium, we hypothesized that incipient IPMNs may belong to the IPMN pathway ( Fig. 1 ).
Mutations in GNAS at codon 201 have recently been identified as a hallmark molecular alteration of IPMNs (prevalence B66%). 6 Interestingly, GNAS mutations seem to be an early event in IPMN development for several reasons. First, a majority of histologically lowgrade IPMNs harbor this mutation. 6 Second, a recent study demonstrated that GNAS mutations can be identified in duodenal fluid samples even before the IPMN lesion can be identified on radiologic imaging. 8 We therefore used GNAS mutations as a marker of the "IPMN pathway," to study incipient IPMNs. Our longterm goal is to improve the clinical and pathogenetic understanding of small pancreatic cysts.
MATERIALS AND METHODS

Patients and Tissues
This study was approved by the Johns Hopkins Review Board and the review boards of collaborating institutions. To identify relevant tissue specimens, the prospectively maintained surgical pathology databases of Johns Hopkins University, Vanderbilt University, and University of Bonn were queried for incipient IPMNs by diagnosis according to the final histology report of pa-tients who underwent pancreatic surgery. Additional lesions were acquired by meticulous random review of pancreatectomy specimens.
Histology
The histologies of all tumors included were reassessed by 2 experts in pancreatic pathology (R.H.H. and A.M.) on the basis of the most recent World Health Organization guidelines. 12 Briefly, incipient IPMNs were recognized as small cyst-forming lesions composed of tall papillae lined by mucin-producing columnar cells. By definition, all were <1 cm in maximum diameter. The epithelial lining was classified as gastric-foveolar, pancreatobiliary, intestinal, or oncocytic using previously described criteria. 12 The incipient IPMNs were further stratified according to the degree of cellular dysplasia into low-grade, intermediate-grade, and high-grade dysplasia (also known as carcinoma in situ).
Manual Microdissection
Formalin-fixed and paraffin-embedded tissue blocks containing lesional tissue were sectioned (10 to 30 sections at 10 mm thickness), deparaffinized, stained, and microdissected on a stereomicroscope using a sterile needle (SMZ1500; Nikon, Tokyo, Japan). An average of 1000 to 2000 cells were collected from each lesion, and the neoplastic cellularity was estimated to be >80%. Afterward, genomic DNA was extracted using the QIAamp DNA Micro Kit (Qiagen Inc., Valencia, CA).
Digital Ligation Polymerase Chain Reaction
The DNA amplification and ligation assays were performed as described in previous publications. [13] [14] [15] [16] [17] 
RESULTS
Clinicopathologic Parameters
This study was performed using formalin-fixed and paraffin-embedded tissues from surgical pathology archives of 3 centers with focus on hepatopancreatobiliary diseases. Detailed patient information is provided in Table 1 .
We included lesions from 7 male and 12 female patients who had a median age of 63 years (range, 40 to 76 y). Most lesions (N = 8) were observed in association with a resected pancreatic ductal adenocarcinoma or were found in pancreata resected for ampullary adenocarcinomas (N = 3). One of the incipient IPMNs included arose in a patient with a strong family history of pancreatic cancer.
The median size of incipient IPMNs was 4 mm (range, 2 to 7 mm). The lining epithelium showed mostly intermediate-grade dysplasia (N = 14) and predominantly a gastric-foveolar epithelial subtype (N = 11).
GNAS and KRAS Mutations in Incipient IPMNs
We assessed the mutational status of KRAS and GNAS using a sensitive polymerase chain reaction/ligation method. Genomic DNA was extracted for this purpose from the 21 incipient IPMNs.
Sequencing studies revealed that all incipient IPMN lesions had at least 1 KRAS codon 12 mutation. Most incipient IPMNs had a KRAS G12D (N = 8) or a KRAS G12V (N = 7) mutation. Four incipient IPMNs had a KRAS G12R mutation-one of them with an additional KRAS G12D allele. GNAS mutations were identified in 7 incipient IPMNs (33%) ( Table 1) . Five had a solitary GNAS R201H and one a solitary GNAS R201C mutation. One incipient IPMN harbored a GNAS R201H as well as a GNAS R201C mutation. On histopathologic assessment, incipient IPMNs with a GNAS mutation had a median size of 5 mm (range, 2 to 7 mm) and displayed in majority a gastric-foveolar subtype (N = 5) with intermediate dysplasia (N = 5).
DISCUSSION
Small pancreatic cysts are increasingly diagnosed. IPMN is the most frequent cystic neoplasm of the pancreas and is now well understood clinically and on a molecular level. [4] [5] [6] [7] [8] [9] An IPMN has been defined as a grossly visible cyst >1 cm in maximum diameter with characteristic papillary mucin-producing epithelium. 12 IPMNs can be differentiated from microscopic PanINs on the basis of not only morphology and size but also distinct molecular pathways. 18, 19 For instance, GNAS codon 201 mutations have been identified as a hallmark molecular alteration occurring in a majority of IPMNs. 5, 6, 20 This genetic alteration is virtually absent in PanINs and in pancreatic ductal adenocarcinoma arising without associated IPMNs. 18, 21 The term "incipient IPMN" has been used for intraductal lesions <1 cm that are composed of an IPMNlike epithelium. Lesions of this histopathologic "gray area" are occasionally seen in the context of sporadic multifocal IPMNs 11 or in pancreata of familial pancreatic cancer kindreds. 10 They can also be seen in pancreata resected for other tumors or nontumorous diseases; these tiny cysts are found with entirely unknown clinical relevance. It is unclear whether the pathogenetic pathway for incipient IPMNs is along the PanIN-associated or the IPMN-associated pathway. That is, are incipient IPMNs small IPMNs or are they large PanIN lesions? An understanding of incipient IPMNs is also clinically relevant, as even small IPMNs can have a substantial risk for malignant transformation. 22 In the pancreas, GNAS codon 201 mutations appear to be a highly specific marker of IPMNs. Hence, we assessed the prevalence of these molecular alterations in a series of well-characterized incipient IPMNs. GNAS (20q13.3) is a gene that encodes for a protein functioning as a subunit of a stimulatory G-protein a-subunit (Gs-a), a crucial component of numerous signal transduction pathways. Germline mutations in this gene result in the McCune Albright Syndrome with its characteristic pubertas precox, Cafe´-au-lait spots, and polyostotic fibrous dysplasia. 23 Patients with the fibrous dysplasia disorder named Mazabrauds syndrome present with intramuscular myxomas that frequently show activating GNAS mutations. 24 Furthermore, somatic GNAS mutations have been observed in various neoplasms such as renal cell carcinoma, 25 thyroid tumors 26 pituitary adenomas, 27 inflammatory liver tumors, 28 rarely in colorectal cancer, 29 and interestingly quite prevalent in villous adenomas of the colorectum. 30 We found that a large fraction of incipient IPMNs carry a GNAS mutation and that all had KRAS mutations as expected from previous sequencing studies. 5, 6 Incipient IPMNs therefore appear to be part of the IPMN pathway of pancreatic neoplasia. The fact that most lesions were of low-grade or intermediate-grade dysplasia suggests that KRAS and GNAS mutations are both early events in the development of IPMNs. This conclusion is supported by the previous observation that GNAS mutations can be detected in duodenal juice samples even before the patient has a radiologically discernible lesion. 8 Our study has several relevant limitations. We included only a small series of incipient IPMNs as these lesions are only rarely observed in pancreatectomy specimens. According to expert estimates, incipient IPMNs occur in merely 5% of all resected pancreata. Hence, the present cohort was too small to draw final conclusions about associations with demographic or clinicopathologic data, and it is not possible to assess the prognostic impact of incipient IPMNs.
In summary, 33% of incipient IPMNs analyzed harbored a GNAS mutation, suggesting that a large proportion of incipient IPMNs are, as the name suggests, part of the IPMN pathway, and these mutations occur early in this process.
